Showing 11 - 20 of 142
Persistent link: https://www.econbiz.de/10001299749
Persistent link: https://www.econbiz.de/10001713305
Persistent link: https://www.econbiz.de/10005293460
Persistent link: https://www.econbiz.de/10005349946
Persistent link: https://www.econbiz.de/10013477151
Purpose. The paper reviews the Health Utilities Index (HUI®) as a means to describe health status and obtain utility scores reflecting health-related quality of life (HRQL). Materials. The HUI Mark 2 (HUI2) and Mark 3 (HUI3) classification and scoring systems are described. The methods used to...
Persistent link: https://www.econbiz.de/10008549378
Persistent link: https://www.econbiz.de/10005442783
Objective: The aim of this study was to evaluate the cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Design: A retrospective, incremental cost-effectiveness analysis was conducted from a societal...
Persistent link: https://www.econbiz.de/10005449086
The first edition of the Guidelines for Economic Evaluation of Pharmaceuticals: Canada was published in November 1994. At that time, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) was assigned the task of maintaining and regularly updating the Canadian Guidelines....
Persistent link: https://www.econbiz.de/10005449189
Until now, there has been no standardized method of performing and presenting budget impact analyses (BIAs) in Canada. Nevertheless, most drug plan managers have been requiring this economic data to inform drug reimbursement decisions. This paper describes the process used to develop the...
Persistent link: https://www.econbiz.de/10005404836